SHORT COMMUNICATION
Human ribonuclease Dicer inhibition using RNA aptamers
 
More details
Hide details
 
Publication date: 2015-12-21
 
 
BioTechnologia 2014;95(4):259-263
 
KEYWORDS
ABSTRACT
The aim of this invention was to select RNA aptamers that specifically bind human ribonuclease Dicer, which is one of the main enzymes that take part in miRNA biogenesis and the biogenesis of other short regulatory RNAs, and then to find out if pre-selected molecules affect enzyme activity. Other aims of this solution include: 1) using RNA aptamers as ribonuclease Dicer competitive inhibitors; 2) using RNA aptamers that are allosteric ribonucle- ase Dicer inhibitors, 3) identifying RNA aptamers that are selective inhibitors of emergence of selected miRNAs.
REFERENCES (14)
1.
Bartel D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2): 281-297.
 
2.
Blank M., Blind M., (2005) Aptamers as tools for target validation. Curr. Opin. Chem. Biol. 9(4): 336-42.
 
3.
Ellington A.D., Szostak J.W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 46(6287): 818-822.
 
4.
Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.Nature 391(6669): 806-811.
 
5.
Haley B., Zamore P.D. (2004) Kinetic analysis of the RNAi enzyme complex. Nat. Struct. Mol. Biol. 11(7): 599-606.
 
6.
Hammond S.M., Bernstein E., Beach D., Hannon G.J. (2000) An RNA-directed nuclease mediates posttranscriptional gene silencing in Drosophila cells. Nature 404(6775): 293- 296.
 
7.
Macrae I.J., Zhou K., Li F., Repic A., Brooks A.N., Cande W.Z., Adams P.D., Doudna J.A. (2006) Structural basis for doublestranded RNA processing by Dicer. Science 311(5758): 195-198.
 
8.
Nimjee S.M., Rusconi C.P., Sullenger B.A. (2005) Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56: 555-583.
 
9.
Nykanen A., Haley B., Zamore P.D. (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107(3): 309-321.
 
10.
Proske D., Blank M., Buhmann R., Resch A. (2005) Aptamers-- basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69(4): 367-374.
 
11.
Tuerk C., Gold L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249(4968): 505-510.
 
12.
White R.R., Sullenger B.A., Rusconi C.P. (2000) Developing aptamers into therapeutics. J. Clin. Invest. 106(8): 929- 934.
 
13.
Yan A.C., Bell K.M., Breeden M.M., Ellington A.D. (2005) Aptamers: prospects in therapeutics and biomedicine. Front. Biosci. 10: 1802-1827.
 
14.
Zhang K., Nicholson A.W. (1997) Regulation of ribonuclease III processing by double-helical sequence antideterminants. Proc. Natl. Acad. Sci. USA 94(25): 13437-13441.
 
eISSN:2353-9461
ISSN:0860-7796
Journals System - logo
Scroll to top